Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma
Alessandra Romano, Paola Storti, Valentina Marchica, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 19

Showing 19 citing articles:

Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Muthulekha Swamydas, Elena V. Murphy, James J. Ignatz-Hoover, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 83
Microtubule‐targeting agents for cancer treatment: Seven binding sites and three strategies
Xingyu Wang, Benoı̂t Gigant, Xi Zheng, et al.
MedComm – Oncology (2023) Vol. 2, Iss. 3
Open Access | Times Cited: 30
T-cell–redirecting bispecific antibodies in multiple myeloma: a revolution?
Philippe Moreau, Cyrille Touzeau
Blood (2022) Vol. 139, Iss. 26, pp. 3681-3687
Open Access | Times Cited: 34
Pulmonary adverse events associated with monoclonal antibodies approved for multiple myeloma: a pharmacovigilance study based on the FDA adverse event reporting system
Ting Liang, Limei Yan, Junfeng Li, et al.
Expert Opinion on Drug Safety (2025), pp. 1-6
Closed Access
Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells
Maiko Matsushita, Sho Kashiwazaki, Satoshi Kamiko, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 10, pp. 1367-1367
Open Access | Times Cited: 6
Multi-targeted immunotherapeutics to treat B cell malignancies
M. Tommy Gambles, Jiyuan Yang, Jindřich Kopeček
Journal of Controlled Release (2023) Vol. 358, pp. 232-258
Open Access | Times Cited: 4
Modulating macrophage-mediated programmed cell removal: An attractive strategy for cancer therapy
Zhenzhen Li, Bingqian Han, Menghui Qi, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189172-189172
Closed Access | Times Cited: 1
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System
Giuseppe Cicala, Giulia Russo, Vincenza Santoro, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1266-1266
Open Access | Times Cited: 1
Elotuzumab in multiple myeloma
Antonella Bruzzese, Enrica Antonia Martino, Ernesto Vigna, et al.
Expert Opinion on Biological Therapy (2022) Vol. 23, Iss. 1, pp. 7-10
Closed Access | Times Cited: 6
HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable-or intermediate-risk acute myeloid leukemia
Shandong Tao, Dan Zhou, Lixiao Song, et al.
Hematology (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 2
On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future
Vincent Sunder-Plaßmann, Osman Aksoy, Judith Lind, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 12, pp. 1425-1444
Closed Access | Times Cited: 3
Exploring cellular immunotherapy platforms in multiple myeloma
Manh-Cuong Vo, Sunghoon Jung, Van‐Tan Nguyen, et al.
Heliyon (2024) Vol. 10, Iss. 6, pp. e27892-e27892
Open Access
Recent Advances in Multiple myeloma
Elisha Paikray, Anima Rout, Ratikant Tripathy
Biomedical & Pharmacology Journal (2024) Vol. 17, Iss. 1, pp. 557-563
Open Access
Lymphocyte profile in peripheral blood of patients with multiple myeloma
Tereza Dekojová, Hana Gmucová, Diana Macečková, et al.
Annals of Hematology (2024)
Closed Access
Teclistamab Monotherapy for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma
Beatrice Razzo, Alfred L. Garfall
touchREVIEWS in Oncology & Haematology (2023) Vol. 19, Iss. 1, pp. 46-46
Open Access | Times Cited: 1
Treatment Strategies for Multiple Myeloma Treatment and the Role of High-Throughput Screening for Precision Cancer Therapy
Thudzelani Takalani Austin Malise, Ekene Emmanuel Nweke, Mutsa M. Takundwa, et al.
Advances in experimental medicine and biology (2023), pp. 167-185
Closed Access | Times Cited: 1
Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials
Francisco Cézar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Artur de Oliveira Macena Lôbo, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 4, pp. 360-360
Open Access
Fármacos Anticorpos Monoclonais para o Tratamento do Câncer: uma Perspectiva Brasileira
Júlia Teixeira de Menezes, Maria Carolina Theisen, Vanessa da Costa Flores, et al.
Revista Brasileira de Cancerologia (2024) Vol. 70, Iss. 1
Open Access
Precision Medicine in Therapy of Non-solid Cancer
Ines Schmidts, Torsten Haferlach, Gregor Hoermann
Handbook of experimental pharmacology (2022), pp. 35-64
Closed Access
Page 1

Scroll to top